Skip to main content

Sponsored By

Interview with the Innovators
ADC Therapy Treatment HER2+ and HER2-Low mBC

Setting Appropriate Patient Goals of Therapy

Videos - Interview with the Innovators

In the third video of this series, knowledgeable advance practice providers contribute their viewpoints on the attributes of targeted antibody drug conjugate therapy for mBC that may help some patients fulfill their treatment goals.

Tajuana Bradley, MS, FNP-BC
Nurse Practitioner
Georgia Cancer Specialists
Northside Hospital Cancer Institute
Lawrenceville, GA
Ryan Haumschild, PharmD, MS, MBA, CPEL
Vice President, Ambulatory Pharmacy
Emory Healthcare
Atlanta, GA
Abbey J. Kaler, MS, APRN, FNP-C
Supervisor,
Advanced Practice Providers, Advanced Breast Cancer (ABC) Program
The University of Texas MD Anderson Cancer Center
Houston, TX
Susie Ulloa, RN, OCN, ONN-CG
Oncology Nurse Navigator
APT. Inc.
Gainesville, FL

Interview with the Innovators Presents:
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC

As the breast cancer landscape continues to evolve with new research, it is imperative for advance practice providers and nurse navigators to have a comprehensive understanding of the disease state and side effect management. This educational series is intended to enhance the knowledge of advanced practice providers and navigators around a treatment option now available to a new patient population with mBC. The publishers of JONS and JHOP are pleased to present this 6-part video series featuring expert commentary:

Related Items
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Videos published on November 12, 2025 in Interview with the Innovators
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
Jamie Carroll, APRN, CNP, MSN
Videos published on November 10, 2025 in Interview with the Innovators
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
Heather Moore, PharmD, BCOP, CPP
Videos published on November 5, 2025 in Interview with the Innovators
Insights From the TRADE Study: Optimizing Abemaciclib Dose Escalation for Better Tolerability and Adherence
Heather Moore, PharmD, BCOP, CPP
Videos published on November 3, 2025 in Interview with the Innovators
TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care
Erica Mayer, MD, MPH
Videos published on October 28, 2025 in Interview with the Innovators
Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability
Erica Mayer, MD, MPH
Videos published on October 24, 2025 in Interview with the Innovators
Management of Adverse Events in ADC Therapy: A Case-Based Exchange
Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL
Videos published on June 27, 2025 in Case-Based Exchanges
Importance of Hospital Partnerships for Bispecific Agent Implementation
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 21, 2025 in Interview with the Innovators
EHR Implementation of Bispecific Agents for Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 13, 2025 in Interview with the Innovators
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 10, 2025 in Interview with the Innovators